Trethera

Trethera is a clinical-stage biotechnology company advancing innovative therapies across oncology and autoimmune diseases. Our approach targets the salvage pathway, a key metabolic process that fuels diseased cell growth in cancer, autoimmune diseases, and inflammatory disorders, to disrupt disease progression and improve patient outcomes. With a leadership team composed of experienced scientists, industry veterans and biotech innovators, Trethera is on a mission to not only treat multiple high-impact diseases but also offer hope to patients with limited options. Trethera is dedicated to transforming lives through rigorous science, compassionate care, and meaningful innovation. Investment Opportunity: Trethera is currently raising capital under Regulation D Rule 506(c) offering, open to accredited investors. This preferred funding round will accelerate our next phase of growth and the advancement of our breakthrough therapies. Investors have the opportunity to be part of a company at the forefront of biotech innovation. Now accepting accredited investors for a limited-time seed round opportunity: https://trethera.com/regulationd